Clinical Oncology NGS Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Clinical Oncology NGS Market is Segmented by Technology (Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing & Resequencing Centrifuges), Workflow (Pre-Sequencing, Sequencing, Data Analysis), Application (Screening, Companion Diagnostics, Other Diagnostics), End-use (Hospitals, Clinics, Laboratories, and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers the value (USD million) for the above segments.

Clinical Oncology NGS Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Clinical Oncology NGS Industry Overview

The clinical oncology next-generation sequencing (NGS) market is highly competitive, with several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are Illumina, Inc., Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Agilent Technologies, Myriad Genetics, Beijing Genomics Institute (BGI), Perkin Elmer.

Clinical Oncology NGS Market Leaders

  1. Illumina, Inc.

  2. Thermo Fisher Scientific

  3. F. Hoffmann-La Roche Ltd.

  4. Agilent Technologies

  5. Myriad Genetics

  6. *Disclaimer: Major Players sorted in no particular order
Picture3.png

Global Clinical Oncology NGS Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?